The European Commission on Friday extended the authorization of the Imvanex mpox vaccine to teenagers aged 12 to 17.

With more than 200 mpox-related deaths reported globally, the EMA has approved Imvanex for adolescents aged 12-17 years.

The European Medicines Agency (EMA) has approved the use of Bavarian Nordic’s mpox vaccine in adolescents, increasing the ...

Bavarian's JYNNEOS has also been approved by the U.S. Food and Drug Administration (FDA) but only for adults 18 years and ...

The first 300 doses were administered on Tuesday near the border with the Democratic Republic of Congo, a spokesperson for ...

The African health agency says that Rwanda has started a vaccination campaign against mpox with 1,000 doses it obtained from ...

Mpox, declared a global public health emergency by WHO, has disproportionately affected children and adolescents ...

Gavi, the Vaccine Alliance, will purchase 500,000 doses of MVA-BN, the Bavarian Nordic Mpox vaccine, as part of an ...

Health Minister of Indian state of Kerala, Veena George, said on Thursday that genome sequencing will be conducted to ...

Gavi, the Vaccine Alliance, and Bavarian Nordic A/S have announced a significant advance purchase agreement, securing 500,000 ...

Congo's South Kivu province is at the epicenter of the world’s latest mpox outbreak, in what the World Health Organization ...

One dose of modified vaccinia Ankara-Bavarian Nordic (MVA-BN) vaccine is moderately effective against mpox infection in at-risk communities.